Protein Therapeutics Market to Reach USD 857.2 Billion by 2036 from USD 401.8 Billion in 2025, Expanding at 7.1% CAGR

The global protein therapeutics market was valued at USD 401.8 billion in 2025 and is projected to reach USD 857.2 billion by 2036, expanding at a CAGR of 7.1% from 2026 to 2036. Increasing prevalence of chronic and rare diseases, growing adoption of biologic medicines, rising demand for monoclonal antibodies and recombinant proteins, and continuous advancements in protein engineering and biopharmaceutical technologies are supporting market expansion.

Protein therapeutics are protein-based medicines used to prevent, manage, or treat a broad range of diseases and disorders. Major categories include monoclonal antibodies, recombinant proteins, fusion proteins, insulin, plasma-derived proteins, and therapeutic enzymes. Their high specificity and ability to modulate complex biological pathways have made them an important component of modern medicine.

Protein therapeutics are widely used across oncology, autoimmune diseases, diabetes, hematology, cardiovascular diseases, infectious diseases, neurological disorders, and rare genetic conditions. Advances in recombinant DNA technology, cell culture, purification, formulation, and protein engineering have enabled the development of increasingly specific and clinically effective therapies.

The market is also benefiting from the increasing commercialization of biosimilars and continued approval of innovative biologics. Pharmaceutical and biotechnology companies are investing in new indications, advanced delivery systems, product life-cycle management, and next-generation protein modalities. Meanwhile, increasing healthcare expenditure, improving access to advanced therapies, and greater awareness of targeted treatment approaches are expected to sustain demand for protein therapeutics through 2036.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2035

Rising Burden of Chronic Diseases Drives Protein Therapeutics Market Growth

The increasing prevalence of chronic and rare diseases worldwide is one of the major factors driving the protein therapeutics market. Cancer, diabetes, autoimmune diseases, cardiovascular conditions, and neurological disorders continue to place substantial pressure on healthcare systems and patients. Growing awareness and improved diagnostic capabilities are also leading to greater identification of rare and complex diseases, creating demand for specialized therapeutic approaches.

Monoclonal antibodies and other protein-based medicines are increasingly used in oncology for the treatment of solid tumors and blood cancers. Their ability to selectively target disease-associated molecules can provide therapeutic benefits while potentially reducing the impact on healthy tissues compared with less targeted treatment approaches.

Biologic therapies are also widely used for autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. These therapies can modulate immune responses and support disease management.

In metabolic diseases, insulin and other recombinant proteins remain important treatment options for diabetes and associated complications. Therapeutic enzymes, coagulation factors, and other specialty proteins are similarly important in the treatment of rare and inherited disorders.

The aging population, lifestyle changes, increasing disease awareness, and improved diagnostic capabilities are contributing to the growing need for advanced therapies. As the burden of chronic and rare diseases continues to increase, demand for protein-based medicines is expected to support long-term market development.

Growing Adoption of Biosimilars Drives Market Expansion

Increasing availability and adoption of biosimilars and biobetters are creating additional momentum in the protein therapeutics market. The expiration of patents and exclusivity periods for several established biologic medicines has created opportunities for manufacturers to introduce biosimilar alternatives.

Biosimilars are biological medicines that are highly similar to an approved reference biologic and do not have clinically meaningful differences in safety, purity, or potency. Their availability can expand patient access to protein-based therapies while introducing additional competition into the biologics market.

Biosimilar adoption has become particularly relevant in oncology, immunology, endocrinology, and hematology, where biologic medicines represent an important component of treatment and pharmaceutical expenditure. Increased competition can contribute to more affordable treatment options and broaden access to established protein therapies.

Regulatory agencies in major markets have also established clearer pathways for biosimilar development and approval. This is encouraging additional pharmaceutical and biotechnology companies to participate in biosimilar development and commercialization.

Biobetters provide another avenue for innovation. These modified biologic therapies are designed to improve characteristics such as efficacy, safety, pharmacokinetic performance, dosing convenience, or other product attributes. Pharmaceutical companies are therefore combining life-cycle management with product improvements to maintain competitiveness as established biologics face increasing competition.

The growing availability of biosimilars and biobetters is expected to contribute to market expansion by improving access to protein therapies while encouraging innovation across the biologics ecosystem.

R&D Investment Accelerates Protein Therapeutics Innovation

Continued investment in research and development by pharmaceutical and biotechnology companies is creating significant opportunities in the protein therapeutics market. Advances in protein engineering, molecular biology, recombinant technology, cell culture, purification, and formulation are enabling the development of increasingly targeted and effective therapies.

Research efforts are extending beyond conventional monoclonal antibodies toward bispecific antibodies, multispecific antibodies, fusion proteins, and other advanced protein modalities. These technologies can provide new mechanisms for addressing complex diseases and expanding therapeutic options.

Companies are also focusing on improving the stability, specificity, half-life, delivery, and manufacturing efficiency of protein therapeutics. Improvements in these characteristics can potentially reduce dosing frequency, increase patient convenience, and improve treatment outcomes.

The continued prevalence of cancer, autoimmune disorders, metabolic diseases, and neurological conditions is creating demand for novel biologic therapies. Increasing emphasis on precision medicine is further supporting the development of protein therapeutics designed around specific biological targets.

Strategic alliances, licensing agreements, partnerships, mergers, and acquisitions can accelerate the development and commercialization of innovative protein-based medicines. As companies pursue differentiated protein modalities and validated therapeutic targets, continued R&D investment is expected to create new products, expand therapeutic applications, and strengthen commercial opportunities.

Monoclonal Antibodies Dominate the Protein Therapeutics Market

The monoclonal antibodies (mAbs) segment accounted for approximately 41.2% of the global protein therapeutics market in 2025, making it the leading product modality. The segment benefits from extensive clinical applications and widespread commercial adoption across oncology, autoimmune diseases, inflammatory disorders, and other therapeutic areas.

Monoclonal antibodies are important protein therapeutics because they can selectively target molecules associated with specific diseases. This targeted approach can improve therapeutic effectiveness and provide advantages over conventional treatment approaches in certain applications.

Oncology represents a major application area for monoclonal antibodies, with numerous antibody-based therapies approved for solid tumors and hematological cancers. The technology is also widely used in autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and asthma.

Leading pharmaceutical and biotechnology companies continue to invest in monoclonal antibody research, manufacturing capacity, formulation, and life-cycle management. Advances in antibody engineering have further improved the characteristics and potential applications of these therapies.

The broad clinical application of monoclonal antibodies, established commercial presence, and continuous innovation are expected to maintain the segment's leading position in the global protein therapeutics market.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2035

North America Leads Protein Therapeutics Market

North America dominated the global protein therapeutics market in 2025, accounting for approximately 46.0% of total market revenue. The region's leading position is supported by its advanced biopharmaceutical industry, established healthcare infrastructure, strong research ecosystem, and widespread adoption of innovative biologic therapies.

The region is home to numerous leading pharmaceutical and biotechnology companies involved in the discovery, development, manufacturing, and commercialization of protein-based medicines. These companies operate across therapeutic areas including oncology, autoimmune diseases, diabetes, rare disorders, and hematological conditions.

The U.S. represents a major contributor to the North American market because of its large patient population, high healthcare expenditure, advanced biopharmaceutical capabilities, and extensive use of biologic therapies. A well-developed clinical research environment also supports the introduction of new protein therapeutics and additional indications for existing products.

The presence of biologics manufacturers, specialized treatment centers, research institutions, and established healthcare infrastructure facilitates access to protein-based therapies. Growing adoption of monoclonal antibodies, recombinant proteins, fusion proteins, and insulin therapies is further supporting regional demand.

North America's strong biotechnology ecosystem and continued focus on precision medicine and targeted therapies are expected to reinforce its leading position in the global protein therapeutics market throughout the forecast period.

Competitive Landscape

The global protein therapeutics market is characterized by significant investments in research and development, product innovation, strategic collaborations, manufacturing expansion, and life-cycle management. Leading pharmaceutical and biotechnology companies are expanding their protein therapeutic portfolios while pursuing innovative treatment modalities and new indications.

Prominent companies operating in the market include Amgen Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Novo Nordisk A/S, Merck & Co., Inc., Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca PLC, Gilead Sciences, Inc., Bristol-Myers Squibb, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Novartis AG.

Companies are competing through development of innovative biologics, monoclonal antibodies, recombinant proteins, advanced protein modalities, biosimilars, and biobetters. Strategic partnerships, licensing arrangements, acquisitions, expanded manufacturing capabilities, and product life-cycle management are also important competitive strategies.

Continued investment in protein engineering and advanced manufacturing technologies is expected to influence competition as companies seek to improve therapeutic efficacy, dosing convenience, manufacturing efficiency, and market access.

Key Developments in Protein Therapeutics Market

In April 2026, Eli Lilly received U.S. Food and Drug Administration approval for orforglipron, a GLP-1 receptor agonist intended for the treatment of obesity. The approval represented an important development in metabolic therapies because of its oral formulation compared with injectable treatment options.

In December 2025, Roche announced that the European Commission approved Gazyva/Gazyvaro (obinutuzumab) for adults with active lupus nephritis. The approval was based on evidence demonstrating superior renal response compared with standard therapy in Phase II and Phase III clinical trials.

In December 2025, UPLIZNA (inebilizumab-cdon) received U.S. FDA approval for the treatment of generalized myasthenia gravis in adults. The therapy is a CD19-directed B-cell targeted treatment for patients who are positive for anti-AChR or anti-MuSK antibodies.

In April 2025, Sanofi and Regeneron received FDA approval for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria in patients who continue to experience symptoms despite antihistamine treatment. The approval represented an important development in targeted treatment for the condition.

Protein Therapeutics Market Segmentation

Based on product modality, the global protein therapeutics market is segmented into monoclonal antibodies, recombinant proteins, fusion proteins, insulin, plasma-derived proteins, therapeutic enzymes, and others. Monoclonal antibodies represented the leading segment in 2025 due to their broad clinical and commercial applications.

By manufacturing technology, the market is categorized into mammalian cell culture technology, microbial expression technology, and plasma fractionation technology. Advances in biopharmaceutical manufacturing are supporting improvements in production efficiency, scalability, purity, and consistency.

Based on therapeutic area, the market covers oncology, immunology and autoimmune diseases, metabolic and endocrine disorders, hematology, cardiovascular diseases, ophthalmic disorders, infectious diseases, respiratory diseases, neurological disorders, and other therapeutic areas.

By route of administration, protein therapeutics are segmented into intravenous, subcutaneous, intramuscular, oral, and other routes. Developments in drug delivery are increasingly important for improving patient convenience and treatment adherence.

Based on end user, the market is divided into hospitals, clinics, research laboratories, pharmaceutical and biotechnology companies, and others.

Geographically, the global protein therapeutics market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Key countries include the U.S., Canada, Germany, U.K., France, Italy, Spain, Switzerland, the Netherlands, China, India, Japan, South Korea, Australia & New Zealand, Brazil, Mexico, Argentina, GCC countries, and South Africa.

Protein Therapeutics Market Outlook

The global protein therapeutics market is expected to maintain consistent growth through 2036 as the prevalence of chronic and rare diseases increases and healthcare systems continue to adopt targeted biologic therapies. The market is projected to expand from USD 401.8 billion in 2025 to USD 857.2 billion by 2036, advancing at a CAGR of 7.1% from 2026 to 2036.

The increasing use of protein-based medicines across oncology, autoimmune disorders, metabolic diseases, hematology, rare diseases, and other therapeutic areas is expected to remain a major growth catalyst. Monoclonal antibodies are likely to retain their leading position due to their broad clinical applications and extensive commercial adoption.

Biosimilar commercialization is expected to further influence the market by expanding access to established biologic therapies and increasing competition. Meanwhile, biobetters and next-generation protein modalities can provide pharmaceutical and biotechnology companies with opportunities to differentiate their portfolios.

Research and development investment will remain central to market evolution. Advances in protein engineering, recombinant technologies, formulation, delivery systems, and manufacturing processes are expected to support the development of more targeted and patient-focused therapies.

North America is expected to remain a major regional market due to its strong biopharmaceutical industry, advanced healthcare infrastructure, extensive research capabilities, and high adoption of innovative biologics. Continued expansion of healthcare access and biologic treatment capabilities in developing markets is also expected to create new opportunities.

As pharmaceutical and biotechnology companies continue to pursue innovative protein modalities, new therapeutic indications, improved delivery systems, biosimilars, and precision medicine approaches, protein therapeutics are expected to remain a central component of modern biopharmaceutical development through 2036.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=2035<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Allergy Immunotherapy Market

Atopic Dermatitis Drugs Market

Autoimmune Disease Therapeutics Market

Asthma and COPD Drugs Market

Neuroprotection Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com